United Therapeutics (UTHR) reported Q1 net income Wednesday of $6.63 per diluted share, up from $6.17 a year earlier.
Analysts polled by FactSet expected $6.48.
Revenue for the quarter ended March 31 was $794.4 million, up from $677.7 million a year earlier.
Analysts surveyed by FactSet expected $729.3 million.